Growth Hormone Peptides: CJC-1295, Ipamorelin, MK-677 & Sermorelin Compared

Growth hormone (GH) peptides do not contain growth hormone. Instead, they stimulate your pituitary gland to produce and release more of your own GH through two main pathways:

Pathway 1 — GHRH analogs (CJC-1295, sermorelin): These mimic growth hormone-releasing hormone (GHRH), the natural signal that tells your pituitary to produce GH. They amplify the existing GH release cycle.

Pathway 2 — Ghrelin mimetics (ipamorelin, MK-677, GHRP-6): These mimic ghrelin (the "hunger hormone"), which acts on a completely different receptor (GHS-R1a) to trigger GH release. They create additional GH pulses beyond the normal cycle.

Why stacking works: Combining one compound from each pathway (e.g., CJC-1295 + ipamorelin) activates both GH release mechanisms simultaneously. Published research on GHRH + GHRP combinations shows synergistic GH output — the combination produces more GH than either compound alone.

Key difference from HGH: Synthetic growth hormone (somatropin) provides a flat, continuous GH level. Peptides produce pulsatile GH release that more closely mimics natural physiology. This is theorized to produce fewer side effects, though direct comparison trials are lacking.

What it is: A modified version of GHRH (growth hormone-releasing hormone) with 29 amino acids plus a Drug Affinity Complex (DAC) that extends its half-life dramatically.

Two versions exist: - CJC-1295 with DAC: Half-life of 8-10 days. Produces sustained, continuous GH elevation. Fewer injections needed (1-2x per week). - CJC-1295 without DAC (Mod GRF 1-29): Half-life of ~30 minutes. Produces acute GH pulses similar to natural physiology. Requires daily injection (typically before bed).

Human evidence: Teichman et al. (2006) showed CJC-1295 with DAC produced dose-dependent increases in GH (2-10 fold) and IGF-1 (1.5-3 fold) lasting 6-14 days after a single injection. Multiple ascending-dose studies confirmed sustained GH elevation.

Typical protocol: CJC-1295 with DAC: 2 mg subcutaneously 1-2x per week. Without DAC: 100-300 mcg subcutaneously daily, typically combined with ipamorelin before bed.

Side effects: Water retention, headache, flushing at injection site, potential insulin sensitivity effects. CJC-1295 with DAC may suppress natural GH pulsatility due to continuous stimulation.

FDA status: Category 2 (restricted from compounding as of 2023).

What it is: A selective growth hormone secretagogue peptide (5 amino acids) that acts on the ghrelin receptor (GHS-R1a) to stimulate GH release.

Why "clean": Unlike older ghrelin mimetics (GHRP-6, GHRP-2), ipamorelin does not significantly increase cortisol (stress hormone), prolactin, or appetite. This selectivity makes it the best-tolerated GH secretagogue in clinical use.

Human evidence: Phase 2 clinical trial data (Schwahn et al., 2001) in postoperative patients showed ipamorelin safely and selectively stimulated GH release. Multiple dose-finding studies confirmed dose-dependent GH increases without affecting cortisol or prolactin at therapeutic doses.

Typical protocol: 200-300 mcg subcutaneously 1-3x daily. Most commonly dosed before bed (aligning with natural nighttime GH pulse) or split into morning and evening doses. Often combined with CJC-1295 without DAC.

Side effects: Generally well-tolerated. Mild and transient effects may include head rush, lightheadedness at first injection, and vivid dreams. Less appetite stimulation than MK-677 or GHRP-6.

FDA status: Category 2 (restricted from compounding as of 2023).

What it is: A non-peptide (small molecule) oral ghrelin mimetic. Technically not a peptide, but universally grouped with GH peptides because it acts on the same receptor.

The appeal: No injections. Take a pill. This makes it the most convenient GH-elevating option and the only one available orally.

Human evidence: MK-677 has the most extensive human data of any GH secretagogue: - 1-year RCT in 65 elderly adults: 97% increase in GH, IGF-1 restored to youthful levels. BUT no improvement in strength or physical function, and insulin sensitivity worsened (Nass et al., 2008). - 2-month trial in obese subjects: increased fat-free mass by 3 kg and basal metabolic rate. BUT fasting glucose also increased (Svensson et al., 1998). - Diet study: reversed protein catabolism during caloric restriction (Murphy et al., 1998).

The problem: Despite reliably raising GH and IGF-1, MK-677 has consistently failed to translate those increases into meaningful functional improvements in clinical trials. It also causes significant appetite increase and insulin resistance.

Typical protocol: 10-25 mg orally once daily, typically at bedtime. Lower doses (10 mg) are sometimes recommended for those concerned about blood sugar effects.

Side effects: Increased appetite (significant), water retention and bloating, elevated fasting blood sugar, potential insulin resistance with long-term use, lethargy, vivid dreams. These side effects are more pronounced than with injectable GH peptides.

FDA status: Not FDA-approved. WADA-prohibited. Research compound only.

What it is: The first 29 amino acids of natural GHRH. Previously FDA-approved (1997-2008) as Geref for diagnosing and treating pediatric growth hormone deficiency.

Historical significance: Sermorelin was the first GH-releasing peptide to receive FDA approval, providing the longest clinical safety record of any compound in this class.

Why it fell out of favor: CJC-1295 is a modified version of the same GHRH sequence with added amino acid substitutions that dramatically improve stability and half-life. Sermorelin has a very short half-life (~10 minutes), requiring daily injection and producing less robust GH elevation than CJC-1295.

Current use: Still prescribed by some peptide therapy clinics, particularly for those who prefer a compound with a longer clinical safety history. Often chosen for "entry-level" GH peptide therapy.

Typical protocol: 200-300 mcg subcutaneously daily at bedtime. Sometimes combined with ipamorelin.

Side effects: Generally well-tolerated. Injection site reactions, headache, flushing, dizziness. Similar profile to CJC-1295 but at lower efficacy.

FDA status: FDA approval was voluntarily withdrawn in 2008 (commercial reasons, not safety). Currently available through compounding pharmacies.

The most common GH peptide protocols in clinical practice combine a GHRH analog with a ghrelin mimetic:

Most popular stack — CJC-1295 (no DAC) + Ipamorelin: - CJC-1295: 100 mcg + Ipamorelin: 200-300 mcg - Injected together subcutaneously, typically at bedtime - Duration: 3-6 months, sometimes with 1-month off periods - Rationale: Dual-pathway GH stimulation, clean side effect profile

Convenience stack — CJC-1295 with DAC + Ipamorelin: - CJC-1295 with DAC: 2 mg 1-2x per week - Ipamorelin: 200-300 mcg daily at bedtime - Rationale: Fewer CJC injections while maintaining daily ipamorelin pulses

Oral option — MK-677 standalone: - 10-25 mg daily at bedtime - Often used by those who want to avoid injections entirely - Monitor fasting glucose and HbA1c every 3 months

Entry-level — Sermorelin + Ipamorelin: - Sermorelin: 200 mcg + Ipamorelin: 200 mcg at bedtime - Considered the most conservative approach

Important caveat: None of these stacking protocols have been validated in controlled clinical trials. They are based on the pharmacology of each individual compound and clinical observation. Blood work monitoring (IGF-1, fasting glucose, insulin, HbA1c) is recommended at baseline, 6 weeks, and every 3 months.

*This content is for educational purposes only. Growth hormone peptides are prescription medications in clinical settings. Consult a healthcare provider before use.*